BTIG reaffirmed its 'Buy' rating for Glaukos and increased the price target to $202, citing strong sales growth. U.S. glaucoma sales rose 64% to $118.5 million, driven by the iDose TR product, while Corneal Health revenues grew 48% to $30.4 million, supported by Epioxa. Glaukos raised its 2026 revenue guidance to $680-$700 million and maintains high gross margins of about 85%. Despite this positive outlook, some risks remain, including physician workflow challenges and potential margin pressure, leading Zacks Equity Research to maintain a 'Hold' rating.
Piper Sandler raised AbbVie's price target to $303, indicating a potential 13.92% upside from its current price of $265.97. This reflects positive expectations for the biopharmaceutical company's future performance. Institutional investors like J. M....
Berkshire Hathaway has allocated 29.7% of its $356 billion investment portfolio to just two artificial intelligence stocks. This significant concentration underscores the growing confidence and interest in AI technologies as key drivers of future gro...
Wolfe Research has increased its price target for Fox Corporation to $93, indicating a strong positive outlook for the media company. This new target suggests a potential 54% gain from the current stock price of around $60.39, well above its 52-week ...
Autodesk, a major design software company with a market cap of about $53 billion, has seen its stock rise 15.26% over the past month, outperforming its sector and the S&P 500. Despite a recent "Neutral" rating from Citigroup and some daily price fluc...
Hemostemix Inc. announced a presentation by Dr. William Shankle on vascular cognitive impairment and the clinical trial of VesCell™, an autologous stem cell therapy aimed at treating vascular dementia. VesCell™ promotes blood vessel regeneration and ...
